Skip to main content

Table 4 Multivariate analysis of factors associated with outcomes of patients with pre-transplantation MRD who underwent allo-SCT both in the retrospective study and the prospective study (n = 141)

From: Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Covariate Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Relapse
 Disease status (CR1 vs. CR > 1) 4.736 2.113–10.617 <0.001 5.852 2.569–13.652 <0.001
 Transplant modality 0.318 0.142–0.712 0.005 0.360 0.159–0.813 0.014
 Chronic GVHD (yes vs. no) 0.834 0.712–0.977 0.024 0.793 0.669–0.939 0.007
 FLT3-ITD (yes vs. no) 2.710 0.914–8.041 0.072    
Transplant-related mortality
 Recipient age 1.051 0.998–1.108 0.061    
 Neutrophil engraftment 1.213 1.019–1.445 0.030 1.213 1.019–1.445 0.030
Leukemia-free survival
 Disease status (CR1 vs. CR > 1) 3.542 1.715–7.318 0.001 4.554 2.127–9.752 <0.001
 Transplant modality 0.300 0.149–0.602 0.001 0.334 0.165–0.677 0.001
 Chronic GVHD (yes vs. no) 0.812 0.705–0.934 0.004 0.783 0.675–0.909 0.001
 FLT3-ITD (yes vs. no) 2.501 0.951–6.575 0.063    
Overall survival
 Disease status (CR1 vs. CR > 1) 2.634 1.171–5.923 0.019 2.269 1.002–5.137 0.049
 Transplant modality 0.309 0.143–0.670 0.003 0.340 0.155–0.743 0.007
  1. All variables were first included in the univariate analysis; only variables with P < 0.1 were included in the Cox proportional hazards model with time-dependent variables
  2. Abbreviations: MSDT human leukocyte antigen-matched sibling donor transplantation, HR hazard ratio, CI confidence interval, EBMT European Group for Blood and Marrow Transplantation